The epidermal growth factor receptor (EGFR) is a promising target in the treatment of
advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are …

Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …

Background Approximately 150,000 people were diagnosed with non-small cell lung cancer
(NSCLC) in the United States in 2005. Most presented with inoperable advanced-stage …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been
extensively investigated in previously treated advanced non-small-cell lung cancer …

PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …

Background: This meta-analysis evaluated the efficacy and toxicity of gefitinib with other
commonly used drugs in different treatment settings and epidermal growth factor receptor …

The majority of non-small cell (NSC) lung cancers express epidermal growth factor receptor
(EGFR). Many studies have evaluated the clinical effect from targeted therapy achieved by …

Importance of the field: The epidermal growth factor receptor (EGFR) is a leading target for
treatment of non-small-cell lung cancer (NSCLC). Recent trials of the small-molecule EGFR …

Epidermal growth factor receptor tyrosine kinase inhibitors represent a new treatment option
for patients with advanced nonsmall cell lung cancer (NSCLC). This retrospective study …

Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
their long-term prognosis remains poor. Epidermal growth factor receptor (EGFR)-targeted …